As global markets experience mixed movements, with small-cap and value stocks outperforming their large-cap counterparts, investors are increasingly seeking opportunities in lesser-known segments. Penny stocks, often seen as a nod to past market eras, continue to capture attention due to their potential for growth at lower price points. These smaller or newer companies can offer promising returns when backed by robust financials and sound fundamentals. Top 10 Penny Stocks Globally Name Share Price Market Cap Financial Health Rating Lever Style (SEHK:1346) HK$1.44 HK$884.48M ★★★★★★ Foresight Group Holdings (LSE:FSG) £4.455 £511.34M ★★★★★★ IVE Group (ASX:IGL) A$2.86 A$440.84M ★★★★★☆ TK Group (Holdings) (SEHK:2283) HK$2.48 HK$2.11B ★★★★★★ Angler Gaming (NGM:ANGL) SEK3.60 SEK269.95M ★★★★★★ Yangzijiang Shipbuilding (Holdings) (SGX:BS6) SGD3.48 SGD13.7B ★★★★★☆ Integrated Diagnostics Holdings (LSE:IDHC) $0.6275 $364.78M ★★★★★☆ Michelmersh Brick Holdings (AIM:MBH) £0.81 £73.43M ★★★★★★ EDU Holdings (ASX:EDU) A$0.82 A$118.02M ★★★★★☆ Begbies Traynor Group (AIM:BEG) £1.18 £189.9M ★★★★★☆ Click here to see the full list of 3,530 stocks from our Global Penny Stocks screener. Here's a peek at a few of the choices from the screener. Eastern Polymer Group Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Eastern Polymer Group Public Company Limited, with a market cap of THB8.46 billion, manufactures and distributes rubber insulation, automotive products, and plastic packing both in Thailand and internationally through its subsidiaries. Operations: The company's revenue is primarily derived from three segments: Rubber Insulation at THB4.72 billion, Automotive Plastics at THB6.25 billion, and Packaging Plastics at THB2.26 billion. Market Cap: THB8.46B Eastern Polymer Group, with a market cap of THB8.46 billion, is trading at 27.2% below its estimated fair value. The company has shown stable weekly volatility and improved net profit margins from 5.9% to 7.4%. EPG's earnings grew by 19.1% last year, surpassing the Chemicals industry average of 13%, although its five-year earnings trend shows a decline of 9% annually. Its short-term assets exceed both short- and long-term liabilities, and debt is well-covered by operating cash flow (53.5%). The board and management are experienced, contributing to high-quality earnings despite an unstable dividend history recently affirmed with a THB0.07 per share payout. Unlock comprehensive insights into our analysis of Eastern Polymer Group stock in this financial health report. Gain insights into Eastern Polymer Group's outlook and expected performance with our report on the company's earnings estimates. Story Continues SET:EPG Debt to Equity History and Analysis as at Jan 2026 Cosmos Group Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Cosmos Group Co., Ltd. operates in the real estate development and trading sector in China, with a market cap of CN¥2.73 billion. Operations: The company's revenue segment consists of CN¥5.20 billion generated from its operations in China. Market Cap: CN¥2.73B Cosmos Group Co., Ltd. operates with a market cap of CN¥2.73 billion and has shown signs of financial recovery, reporting net income of CN¥94.65 million for the nine months ended September 30, 2025, compared to a net loss in the previous year. The company's short-term assets (CN¥5.7 billion) comfortably cover both its short- and long-term liabilities, while its debt levels have improved over five years from 68.5% to 47.3%. Despite being unprofitable over recent years, management's seasoned leadership and strategic share buybacks may contribute positively to future performance stability amidst ongoing challenges in profitability growth rates. Click to explore a detailed breakdown of our findings in Cosmos Group's financial health report. Evaluate Cosmos Group's historical performance by accessing our past performance report.SZSE:002133 Debt to Equity History and Analysis as at Jan 2026 HARBIN GLORIA PHARMACEUTICALS Simply Wall St Financial Health Rating: ★★★★★★ Overview: HARBIN GLORIA PHARMACEUTICALS Co., LTD is involved in the research, development, production, and sale of pharmaceutical products in China with a market cap of CN¥7.12 billion. Operations: HARBIN GLORIA PHARMACEUTICALS Co., LTD has not reported specific revenue segments. Market Cap: CN¥7.12B Harbin Gloria Pharmaceuticals, with a market cap of CN¥7.12 billion, has demonstrated substantial earnings growth of 265.4% over the past year, significantly outpacing the industry average. The company's financial health is bolstered by more cash than total debt and short-term assets exceeding liabilities. Its debt-to-equity ratio has impressively decreased from 79% to 3.2% over five years, indicating improved leverage management. Despite a low return on equity at 13.7%, its net profit margins have increased to 13%. Recent board changes and amendments in company bylaws reflect strategic shifts that could influence future operations positively or negatively depending on execution effectiveness. Jump into the full analysis health report here for a deeper understanding of HARBIN GLORIA PHARMACEUTICALS. Explore HARBIN GLORIA PHARMACEUTICALS' analyst forecasts in our growth report.SZSE:002437 Financial Position Analysis as at Jan 2026 Seize The Opportunity Click here to access our complete index of 3,530 Global Penny Stocks. Curious About Other Options? AI is about to change healthcare. These 109 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SET:EPG SZSE:002133 and SZSE:002437. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected] View Comments
3 Promising Penny Stocks In Global With Market Caps Of US$300M
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research.
Start Your Free Trial Now!Not sure where to invest today?
Kalkine’s latest research highlights three companies identified through in-depth analysis and market insights.
Explore these research reports to learn about companies currently being tracked by our analysts and make more informed investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...